CD274 and hepatocellular carcinoma: Since both sorafenib and axitinib are the important tyrosine kinase inhibitors, axitinib combined with anti-PDL-1/PD-1 antibodies may also have promising outcomes in advanced HCC treatment, which is waiting for more well-designed RCT to prove it.